Trademark: 88046206
Word
CANNABIS SCIENCE
Status
Dead
Status Code
602
Status Date
Tuesday, August 25, 2020
Serial Number
88046206
Mark Type
4000
Filing Date
Friday, July 20, 2018
Abandoned Date
Thursday, August 13, 2020

Trademark Owner History

Classifications
5 Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Pharmaceutical preparations for the treatment of inflammatory disorders; Pharmaceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Drug delivery agents that provide controlled release of the active ingredients for a wide variety of cannabinoid pharmaceuticals; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical agents affecting digestive organs; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical products for the prevention and treatment of cancer; Therapeutic pharmaceutical for the treatment and prevention of inflammatory bowel disease; Pharmaceutical preparations for use in gastroenterology; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Therapeutic pharmaceutical for the treatment and prevention of neurodegenerative disease; Therapeutic pharmaceutical for the treatment and prevention of neurological disorders; Pharmaceutical preparations for use in neurology; Pharmaceutical preparations and substances for the treatment and prevention of psychiatric diseases and disorders; Therapeutic pharmaceutical for the treatment and prevention of autoimmune conditions; Therapeutic pharmaceutical for the treatment and prevention of inflammation; Pharmaceutical preparations for the treatment and prevention of immune system related diseases and disorders; Therapeutic pharmaceutical for the treatment and prevention of pain; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Therapeutic pharmaceutical for the treatment of infections; Therapeutic pharmaceutical for the treatment of drug-resistant infections; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical agents affecting sensory organs; Analgesic and muscle relaxant pharmaceutical preparations; Pharmaceutical preparations for use in urology; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in opthalmology; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical products for treating respiratory diseases; Pharmaceutical preparations for skin care; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Ocular pharmaceuticals; Antibacterial pharmaceuticals; Pharmaceuticals, namely, anti-infectives

Trademark Events
Aug 25, 2020
Abandonment Notice E-Mailed - Failure To Respond
Aug 25, 2020
Abandonment - Failure To Respond Or Late Response
Feb 12, 2020
Notification Of Non-Final Action E-Mailed
Feb 12, 2020
Non-Final Action E-Mailed
Feb 12, 2020
Non-Final Action Written
Jan 15, 2020
Teas/Email Correspondence Entered
Jan 15, 2020
Correspondence Received In Law Office
Jan 14, 2020
Assigned To Lie
Dec 24, 2019
Teas Response To Office Action Received
Jun 25, 2019
Notification Of Non-Final Action E-Mailed
Jun 25, 2019
Non-Final Action E-Mailed
Jun 25, 2019
Non-Final Action Written
Jun 20, 2019
Assigned To Examiner
Aug 7, 2018
Assigned To Examiner
Jul 25, 2018
New Application Office Supplied Data Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24